Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Eliquis Adherence Not Affected By Patient Education: Study September 2, 2015 Irvin Jackson Add Your Comments Patients taking the controversial anticoagulant Eliquis may be more likely to take the drug dutifully, regardless of whether they are educated about its benefits and potential side effects, according to the findings of new research. In a study presented on Sunday at a conference by the European Society of Cardiology in London, French researchers evaluated patient adherence to Eliquis, which is a part of a new-generation of blood thinners introduced in recent years as a replacement for Coumadin (warfarin). Researchers found that after about six months, nearly 90% of Eliquis users were still taking the pill as directed. The study has not yet been published or peer-reviewed. Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION As part of the study, Eliquis patients were placed into two groups, based on whether they underwent an adherence education program or not, and researchers tracked their use of the drug for six months. Regardless of which group they were in, about 88.3% of the study’s participants were still taking Eliquis as prescribed at the end of the six months. Sponsored by the drug’s manufacturer, Bristol-Myers Squibb, the study is being touted as another advantage for the new anticoagulant over wafarin, which has been the go-to treatment for decades for the prevention of strokes among patients with atrial fibrillation. Eliquis is promoted as easier to use, with the drug makers maintaining that it requires less monitoring than warfarin. Similar claims have been raised by the makers of other new-generation anticoagulants introduced in recent years, including Pradaxa and Xarelto. Amid the aggressive promotion of this new class of anticoagulants, sales for Eliquis, Xarelto and Pradaxa have risen sharply in recent years. However, concerns have also emerged about potential bleeding side effects, as each of the drugs were introduced without a safe and effective reversal agent, resulting in many users suffering severe and sometimes fatal injuries due to uncontrollable bleeding. New Blood Thinner Concerns Pradaxa was the first member of this new generation of blood thinners to hit the market, introduced by Boehringer Ingelheim in October 2012. Xarelto was the second member, introduced by Bayer and Janssen Pharmaceuticals in 2011. Bristol-Myers Squibb introduced Eliquis in 2012. While all blood thinners carry a risk of bleeding, Eliquis, Pradaxa and Xarelto have all been linked to a large number of incidents involving uncontrollable hemorrhaging that doctors were unable to stop. Unlike warfarin, which has an effective antidote available that doctors can use to counteract the blood thinning effects of the drug, there are no approved reversal agents for Eliquis, Pradaxa or Xarelto. As a result, many doctors have reported being unable to control or stop bleeding problems that develop among users of of these new drugs, potentially increasing the risk of severe injury or death. Thousands of Pradaxa lawsuits, Xarelto lawsuits and Eliquis lawsuits have been filed by users of these medications, alleging that the drug makers placed their desire for profits before patient safety by failing to adequately warn about the bleeding risk and the lack of an effective reversal agent. Following several years of litigation, Boehringer Ingelheim agreed to pay about $650 million in Pradaxa settlements in May 2014, to resolve about 4,000 cases, with an average of about $150,000 awarded to former users who experienced severe and sometimes fatal bleeds. However, additional cases continue to be brought by individuals who experienced bleeds. More than 1,200 lawsuits over Xarelto side effects are now pending throughout the federal court system, where the litigation has been centralized before U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana for coordinated pretrial proceedings. A small group of Xarelto cases are being prepared for early trial dates next year, which are designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be offered throughout the litigation. Known as “bellwether” cases, if the drug makers fail to reach Xarelto settlements or another resolution for the cases following these early trials, they could face individual trial dates in courts throughout the U.S. In recent weeks, a growing number of lawsuits over Eliquis bleeding problems have also been filed, raising nearly identical allegations over this most recent addition to the class of anticoagulants. Tags: Bleeding, Blood Clot, Blood Thinner, Eliquis, Pradaxa, Xarelto More Eliquis Lawsuit Stories Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021 Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018 FDA Approves AndexXa as Reversal Agent For Xarelto, Eliquis May 7, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021
Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)